Quidel

The firm's revenues were stronger than expected, due primarily to demand for its COVID-19 molecular diagnostic and rapid immunoassay products.

The index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index in the first half of the year.

The firm also received the CE mark for the test, which uses a reformulated buffer and takes less time to process than a test requiring an RNA extraction step.

The firm's influenza testing revenue reached record highs in January and February, and continued at a high level throughout the end of the quarter.

Seegene said Monday that the Health Canada approval will enable hospitals and licensed labs there to run the assay immediately for high-volume testing.

The GenomeWeb Index fared better than its benchmark counterparts in March, but still fell more than 4 percent.

Now, the assay can also be used with the Applied Biosystems 7500 Standard from Thermo Fisher Scientific, Roche's LightCycler 480, and Qiagen's Rotor-Gene Q.

The EUA is the fifth in less than a week from the FDA for assays to detect SARS-CoV-2 as testing capacity in the US continues to ramp up.

The firm reports it had the highest flu revenue in the fourth quarter since the pandemic flu outbreak of 2009.